Drug Profile
Research programme: psychiatric disorders therapeutics - Arbor Pharmaceuticals
Alternative Names: AR-18 - Arbor PharmaceuticalsLatest Information Update: 26 May 2022
Price :
$50
*
At a glance
- Originator Arbor Pharmaceuticals
- Class Neuropsychotherapeutics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Mental disorders
Most Recent Events
- 25 Jul 2016 Discontinued - Preclinical for Mental disorders in USA (unspecified route)
- 14 Sep 2015 Preclinical trials in Mental disorders in USA (unspecified route) before September 2015 (Arbor Pharmaceuticals pipeline, September 2015)